The renal and cardioprotective effects of SGLT2 inhibitors, which are independent of glycemic control, have clinically important implications, although even with the addition of these drugs, high cardiovascular-related mortality and DKD progression remain as important problems in these patients [5,6]. Here, SLC5A2 is linked to diabetic kidney disease.